Show simple item record

dc.contributor.authorUsmanij, EA
dc.contributor.authorNatroshvili, T
dc.contributor.authorTimmer-Bonte, JNH
dc.contributor.authorOyen, WJG
dc.contributor.authorvan der Drift, MA
dc.contributor.authorBussink, J
dc.contributor.authorGeus-Oei, L-FD
dc.date.accessioned2017-03-06T15:33:19Z
dc.date.issued2017-08
dc.identifier.citationJournal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, 58 (8), pp. 1243 - 1248
dc.identifier.issn0161-5505
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/472
dc.identifier.eissn1535-5667
dc.identifier.doi10.2967/jnumed.116.185314
dc.description.abstract18 F-FDG PET/CT is potentially applicable to predict response to chemotherapy in combination with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). Methods: In 25 patients with advanced nonsquamous NSCLC, 18 F-FDG PET/CT was performed before treatment and after 2 wk, at the end of the second week of first cycle carboplatin-paclitaxel and bevacizumab (CPB) treatment. Patients received up to a total of 4 cycles of CPB treatment. Maintenance treatment with bevacizumab monotherapy was continued until progressive disease without significant treatment-related toxicities of first-line treatment. In the case of progressive disease, bevacizumab was combined with erlotinib. SUV corrected for lean body mass (SUL and SUL peak ) were obtained. PERCIST were used for response evaluation. These semiquantitative parameters were correlated with progression-free survival and overall survival (OS). Results: Metabolic response, defined by a significant reduction in SUL peak of 30% or more after 2 wk of CPB, was predictive of progression-free survival and OS. For partial metabolic responders ( n = 19), the median OS was 22.8 mo. One-year and 2-y OS were 79% and 47%, respectively. Nonmetabolic responders ( n = 6) (stable metabolic disease or progressive disease) showed a median OS of 4.4 mo (1-y and 2-y OS was 33% and 0%, respectively) ( P < 0.001). Conclusion: 18 F-FDG PET/CT after 1 treatment cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients with advanced nonsquamous NSCLC. This enables identification of patients at risk of treatment failure, permitting treatment alternatives such as early switch to a different therapy.
dc.formatPrint-Electronic
dc.format.extent1243 - 1248
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectLung Neoplasms
dc.subjectFluorodeoxyglucose F18
dc.subjectFollow-Up Studies
dc.subjectPredictive Value of Tests
dc.subjectTime Factors
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectBevacizumab
dc.subjectPositron Emission Tomography Computed Tomography
dc.titleThe Predictive Value of Early In-Treatment <sup>18</sup>F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-01-31
rioxxterms.versionofrecord10.2967/jnumed.116.185314
rioxxterms.licenseref.startdate2017-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of nuclear medicine : official publication, Society of Nuclear Medicine
pubs.issue8
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.publication-statusPublished
pubs.volume58
pubs.embargo.termsNot known
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorOyen, Willemen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record